Showing 5851-5860 of 8181 results for "".
- Zasocitinib Demonstrates Biologic-Level Efficacy in Psoriasishttps://practicaldermatology.com/news/zasocitinib-demonstrates-biologic-level-efficacy-in-psoriasis/2486453/Zasocitinib, a selective oral tyrosine kinase 2 (TYK2) inhibitor, demonstrated rapid and robust efficacy with a consistent safety profile in moderate-to-severe plaque psoriasis, according to Phase 3 LATITUDE-PsO-3001 and LATITUDE-PsO-3002 trial results presented by Melinda Gooderham, MD, MSc, at
- Molecular Profiling Reveals Personalized Pathways in Skin Aginghttps://practicaldermatology.com/news/molecular-profiling-reveals-personalized-pathways-in-skin-aging/2486451/A translational biomarker study presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlighted distinct molecular signatu
- Real-World Data Confirm Upadacitinib Effectiveness Across Body Regionshttps://practicaldermatology.com/news/real-world-data-confirm-upadacitinib-effectiveness-across-body-regions/2486450/Real-world evidence from the AD-VISE study demonstrates consistent and robust effectiveness of upadacitinib across body regions in patients with atopic dermatitis (AD), reinforcing outcomes observed in controlled clinical trials, according to data discussed by Melinda Gooderham, MD, MSc, at the A
- Roflumilast Cream Shows Safety and Efficacy in Infants With Atopic Dermatitishttps://practicaldermatology.com/news/roflumilast-cream-shows-safety-and-efficacy-in-infants-with-atopic-dermatitis/2486449/Roflumilast cream 0.05%, a topical phosphodiesterase 4 (PDE4) inhibitor, demonstrated favorable safety and clinically meaningful efficacy in infants with atopic dermatitis (AD), according to results from the Phase 2 INTEGUMENT-INFANT study presented by Lawrence F. Eichenfield, MD, at the American
- IMMpactful: Risankizumab Outperforms Deucravacitinib in Moderate Psoriasis at 16 Weekshttps://practicaldermatology.com/news/immpactful-risankizumab-outperforms-deucravacitinib-in-moderate-psoriasis-at-16-weeks/2486443/Risankizumab achieved higher rates of PASI 90 and PASI 100 compared with deucravacitinib at 16 weeks, alongside greater improvements in patient-reported symptoms and quality of life, new results from the IMMpactful trial suggested.
- Prurigo Nodularis Diagnosis Centers on Clinical Recognition, Not Biopsy, Dr. Elmariah Sayshttps://practicaldermatology.com/news/prurigo-nodularis-diagnosis-centers-on-clinical-recognition-not-biopsy-dr-elmariah-says/2486417/A pragmatic, clinically driven approach is necessary for diagnosing prurigo nodularis (PN), and a biopsy is often unnecessary when key features are present, according to a talk by Sarina Elmariah, MD, FAAD, at the 2026 American Academy of Dermatology (AAD) Annual Meeting. “It is these thre
- Prurigo Nodularis Linked to Elevated Cardiovascular Risk, Expanding View of Systemic Diseasehttps://practicaldermatology.com/news/prurigo-nodularis-linked-to-elevated-cardiovascular-risk-expanding-view-of-systemic-disease/2486416/Growing evidence indicates prurigo nodularis (PN) is associated with increased cardiovascular risk, reinforcing the disease’s systemic nature and the potential consequences of untreated inflammation, according to a talk by Shawn Kwatra, MD, at the 2026 American Academy of Dermatology Annual Meeti
- GLP-1 Receptor Agonists Show Complex, Evolving Role in Alopecia Areatahttps://practicaldermatology.com/news/glp-1-receptor-agonists-show-complex-evolving-role-in-alopecia-areata/2486415/The emerging and sometimes contradictory relationship between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and hair disorders, particularly alopecia areata, was the subject of a talk by Natasha Atanaskova Mesinkovska, MD, PhD, at the 2026 American Academy of Dermatology (AAD) Annual Meet
- What New Secukinumab Data Mean for HS Patients: A Q&A with Dr. April Armstronghttps://practicaldermatology.com/news/what-new-secukinumab-data-mean-for-hs-patients-a-qa-with-dr-april-armstrong/2486412/In the following Q&A, Dr. April Armstrong, professor and chief of dermatology at UCLA and a study coauthor, talks with Practical Dermatology about the importance of new secukinumab data for patients with hidradenitis suppurativa (HS). Speaking on UCB's recently announced top
- Air Pollution Linked to Increased Psoriasis Burden: Meta-Analysishttps://practicaldermatology.com/news/air-pollution-linked-to-increased-psoriasis-burden-meta-analysis/2486409/New research presented at AAD 2026 suggests airborne pollutant particulate matter less than 2.5 microns in diameter (PM2.5), PM10, and NO2 showed the most consistent positive associations with psoriasis incidence in severity, and health care utilization.